SCHEMBL12656244

SCHEMBL12656244

O=S(=O)(Oc1cc(-c2cccc(OCc3ccccc3)c2)nc(N2CCOCC2)n1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.50
CYP2C9 P11712 3/20 0.50
CYP2C19 P33261 3/20 0.50
HSD17B10 Q99714 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TSHR P16473 2/20 0.50
CYP3A4 P08684 1/20 0.50
MAPK1 P28482 1/20 0.50
PRKDC P78527 4/20 0.49
ATM Q13315 2/20 0.49
PIK3CA P42336 7/20 0.49
PIK3CB P42338 2/20 0.49
PIK3CG P48736 2/20 0.49
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP11B2 P19099 1/20 0.46
ALDH1A1 P00352 2/20 0.43
HTT P42858 2/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12656670 0.86 HSD17B10 (0.67) CYP1A2CYP2C9CYP2C19HSD17B10L3MBTL1
SCHEMBL13219299 0.81 PRKDC (0.55) CYP1A2CYP2C9CYP2C19HSD17B10L3MBTL1
SCHEMBL12656555 0.79 L3MBTL1 (0.47) CYP1A2CYP2C9CYP2C19HSD17B10L3MBTL1
SCHEMBL2962548 0.77 PRKDC (0.54) CYP1A2CYP2C9CYP2C19HSD17B10L3MBTL1
SCHEMBL1823306 0.74 PRKDC (0.58) HSD17B10PRKDCATMPIK3CAPIK3CB
SCHEMBL1820931 0.72 PIK3CA (0.70) PIK3CAPIK3CBPIK3CG
SCHEMBL4116337 0.72 CYP11B2 (0.60) HSD17B10L3MBTL1TSHRMAPK1ATM
SCHEMBL1826032 0.72 PIK3CA (0.76) PIK3CAPIK3CBPIK3CG
SCHEMBL13848198 0.71 PIK3CA (0.60) PIK3CAPIK3CBPIK3CGCYP11B2ALDH1A1
SCHEMBL2467713 0.71 PIK3CA (0.57) PRKDCATMPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2316831-B1 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer NOVARTIS AG (CH) 2013-03-06 EP disclosed
EP-2316831-A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer Novartis AG (CH) 2011-05-04 EP disclosed
US-7767669-B2 Small molecule PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-03 US disclosed
US-7767669-B2 Small molecule PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-03 US disclosed
US-20090060912-A1 SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE CHIRON CORPORATION (US) 2009-03-05 US disclosed
US-20090060912-A1 SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE CHIRON CORPORATION (US) 2009-03-05 US disclosed
US-7423148-B2 Small molecule PI 3-kinase inhibitors and methods of their use CHIRON CORPORATION (US) 2008-09-09 US disclosed
US-7423148-B2 Small molecule PI 3-kinase inhibitors and methods of their use CHIRON CORPORATION (US) 2008-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060912-A1 SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE PI4KB, AKT3, PI4KA CYP1A2 3619/4885CYP2C9 3530/4885CYP2C19 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.